abrdn plc Has $1.68 Million Stock Position in Masimo Co. (NASDAQ:MASI)

abrdn plc boosted its stake in shares of Masimo Co. (NASDAQ:MASI) by 91.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 14,334 shares of the medical equipment provider’s stock after buying an additional 6,862 shares during the quarter. abrdn plc’s holdings in Masimo were worth $1,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. State of Michigan Retirement System raised its position in shares of Masimo by 0.9% during the fourth quarter. State of Michigan Retirement System now owns 10,696 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 100 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in Masimo by 140.6% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares in the last quarter. Byrne Asset Management LLC bought a new stake in shares of Masimo in the 4th quarter worth approximately $28,000. Buckhead Capital Management LLC grew its holdings in shares of Masimo by 10.0% during the 3rd quarter. Buckhead Capital Management LLC now owns 2,800 shares of the medical equipment provider’s stock worth $246,000 after purchasing an additional 255 shares in the last quarter. Finally, Cardinal Capital Management increased its position in shares of Masimo by 2.2% during the fourth quarter. Cardinal Capital Management now owns 11,802 shares of the medical equipment provider’s stock valued at $1,383,000 after purchasing an additional 255 shares during the period. 85.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on MASI shares. BTIG Research raised their target price on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. Jefferies Financial Group reaffirmed a “hold” rating and set a $121.00 price objective (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Finally, Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and increased their target price for the stock from $148.00 to $170.00 in a report on Monday, April 15th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $137.43.

Masimo Price Performance

NASDAQ:MASI opened at $136.20 on Tuesday. The firm has a market cap of $7.21 billion, a PE ratio of 90.20 and a beta of 0.97. The company’s 50-day moving average price is $135.80 and its two-hundred day moving average price is $117.18. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. Masimo Co. has a 12 month low of $75.22 and a 12 month high of $190.82.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping the consensus estimate of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The business had revenue of $548.90 million for the quarter, compared to the consensus estimate of $545.69 million. During the same period in the previous year, the business earned $1.32 EPS. Masimo’s revenue was down 11.0% compared to the same quarter last year. On average, equities analysts anticipate that Masimo Co. will post 3.51 EPS for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.